A further setback for Hikma’s proposed generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) in the US has reshaped the race to get the next US Food and Drug Administration approval for a rival to the respiratory blockbuster.
Hikma announced today that it had received a minor complete response letter from the FDA in relation to its abbreviated...




